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Edited by Felix WielandAbstract Perlecan is a multidomain proteoglycan, usually
substituted with heparan sulphate (HS), and sometimes substi-
tuted with both HS and chondroitin sulphate (CS). In this paper,
we describe perlecan puriﬁed from HEK-293 cells substituted
with HS, CS and keratan sulphate (KS). KS substitution was
conﬁrmed by immunoreactivity with antibody 5D4, sensitivity
to keratanase treatment, and ﬂuorophore-assisted carbohydrate
electrophoresis. HEK-293 perlecan failed to promote FGF-
dependent cell growth in an in vitro assay. This study is the ﬁrst
to report perlecan containing KS, and makes perlecan one of
only a very few proteoglycans substituted with three distinct
types of glycosaminoglycan chains.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Perlecan is a modular proteoglycan found in extracellular
and pericellular matrices. Naturally-occurring and engineered
mutations in the gene encoding perlecan (HSPG2) show
unequivocally that perlecan is essential for cell growth, diﬀer-
entiation and tissue function [1–3]. Both the core protein and
the glycosaminoglycan chains confer perlecans ability to mod-
ulate these processes. Perlecan has three glycosaminoglycan
attachment sites located in conserved regions of domain I
[4], and two potential attachment sites located in domain V
[5,6]. Initially, the sites in domain I were thought to be substi-
tuted exclusively with HS chains [7] but they are now known to
have tissue-speciﬁc potential for substitution with both HS and
CS chains [8,9].
The factors that determine the type of glycosaminoglycan at-
tached to perlecan, are controlled by the cell and its environ-
ment. We have found that perlecan from arterial endothelialAbbreviations: HUAEC, human umbilical arterial endothelial cell;
HEK-293, human embryonic kidney cell line; FACE, ﬂuorophore
assisted carbohydrate electrophoresis; EbG, endo-b-galactosidase
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doi:10.1016/j.febslet.2005.07.090cell lineages contains HS chains only [10,11], whereas perlecan
isolated from chondrogenic sources contains both CS and HS.
The mix of chains may inﬂuence how perlecan interacts with
its ligands, including members of the FGF family of growth
factors. To date, there have been no in vivo studies on the bio-
activity of perlecans containing hybrid glycosaminoglycans.
In this study, we have analysed perlecan immunopuriﬁed
from the human embryonic kidney cell line (HEK-293) and
found, surprisingly, that it carries KS, in addition to CS and
HS. This is the ﬁrst report of perlecan substituted with KS.
We also show that HEK-293 perlecan lacks the growth-
promoting properties of other HS-substituted perlecans
suggesting that alterations in glycosaminoglycan substitution
may modulate perlecan bioactivity, and that KS may have a
unique role in determining perlecan function in epithelial cells.2. Materials and methods
Heparin, Media 199, RPMI 1640 medium, EDTA, PMSF, benzam-
idine HCl, and Tris were from The Sigma Chemical Co., Ltd (MO,
USA). D-[3H]-glucosamine hydrochloride was from Amersham Phar-
macia Biotech (Melbourne, Australia). Tissue culture plasticware
was from Nunc or Corning via Medos Company, NSW, Australia.
Fetal Calf Serum (FCS) was a P.A. Biologicals product, Sydney,
Australia. Methyl-[3H]-thymidine was from ICN BioMedicals, NSW,
Australia. Recombinant human FGF-1 and FGF-7 (E. coli) were from
R&D Systems (Bioscientiﬁc Pty Ltd., NSW, Australia). BAF32 cells
expressing the FGF receptor IIIb splice variant (FGFR2IIIb) [12] were
kindly provided by Dr. David Ornitz (St. Louis, MO, USA).
Heparitinase (EC 4.2.2.8; F. heparinum; heparinase III, heparitin-
sulfate lyase), Chondroitinase ABC lyase (EC 4.2.2.4; Proteus
vulgaris), keratanase (Pseudomonas sp.) keratanase II (Bacillus sp.)
and endo-b-galactosidase (EbG; E. freundii) were from Seikagaku Cor-
poration, Japan. Bio-Gel P-10 was from Bio-Rad Australia. Monogels
for the analysis of depolymerised KS were from Prozyme (CA, USA).
N-glycosidase F (EC 3.5.1.52) was from Roche Diagnostics.
2.1. Antibodies
Monoclonal antibodies recognising heparan sulfate (10E4) [13] and
keratan sulfate (5D4) [14] were from Seikagaku Corporation, Japan.
Monoclonal antibody CS56 recognising chondroitin sulfate [15] was
from The Sigma Chemical Co. Ltd (MO, USA). Monoclonal antibody
A76 recognising bovine perlecan core protein has been characterised
elsewhere [16].
2.2. Isolation and puriﬁcation of perlecan from cultured cells
HEK 293 cells were cultured in Media 199 supplemented with pen-
icillin/streptomycin and 10% FCS. Primary cultures of human umbili-
cal arterial endothelial cells (HUAEC) were prepared from freshblished by Elsevier B.V. All rights reserved.
Fig. 1. Identiﬁcation of perlecan glycosaminoglycans by SDS–PAGE/
Western blotting and ELISA assay. (A) Perlecan (1 lg) immunopurifed
from either HUAEC (lanes 1 and 3) or HEK-293 cells (lanes 2, 4, 5 and
6) was electrophoresed on 4–15% SDS gels and analysed by Western
blot with antibodies A76 (lanes 1 and 2), 10E4 (lanes 3 and 4), CS56
(lane 5) and 5D4 (lanes 6). (B) Perlecan puriﬁed from HEK-293 cells
was coated onto ELISA plates, and selected wells incubated with
heparatinase (Hepase), chondroitinase ABC (ChABC) or keratanase
II (Kase). Replicate wells without deglycosidase treatment were
immunodetected with antibodies A76, 10E4, CS56 or 5D4. Wells
treated with heparitinase were immunodetected with antibody 10E4,
those treated with chondroitinase ABC were detected with CS56, and
those treated with keratanase were detected with 5D4.
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scribed [16]. Perlecan in the conditioned medium was puriﬁed by
DEAE-Sepharose chromatography, followed by anti-perlecan aﬃnity
chromatography as described [10] and detected in column fractions
by ELISA with antibodies A76 or 10E4. To radiolabel glycosaminogly-
cans, cells were incubated in the presence of 25 lCi/100 mL [3H]-gluco-
samine in standard medium for 72 h.
2.3. Identiﬁcation of perlecan glycosaminoglycans by ELISA
Glycosaminoglycans present on perlecan were identiﬁed by ELISA,
with and without treatment with deglycosylating enzymes, as described
[10]. Brieﬂy, perlecan (20 lg/mL) was adsorbed onto microtitre plates
for 16 h at 4 C. Selected wells were incubated with 0.05 U/mL glyco-
sidase (one of either chondroitinase ABC, heparatinase, keratanase II
or N-glycosidase F) for 8 h at 37 C, then all wells were blocked with
0.1% casein in PBS. Wells were probed with antibodies A76, 10E4,
CS56 or 5D4.
2.4. Analysis of perlecan KS
To conﬁrm the presence of KS on perlecan, aliquots of [3H]-gluco-
samine labelled perlecan were digested overnight at 37 C with kera-
tanase (20 mU), keratanase II (2 mU) and endo-b-galactosidase
(EbG) (2 mU). The samples were chromatographed on a Biogel P-10
size exclusion column (115 cm · 0.98 cm) equilibrated in 0.1 M ammo-
nium acetate pH 6.8. Fractions (1.0 mL) were collected and analysed
by scintillation counting.
In other experiments, perlecan puriﬁed from HEK-293 cells was ana-
lysed by ﬂuorophore assisted carbohydrate electrophoresis (FACE) to
further conﬁrm the presence of KS. Puriﬁed perlecan (19 lg) was di-
gested with either, 2.5 mU keratanase II or 2.5 mU EbG in 0.1 M
ammonium acetate buﬀer, pH 6.0. The samples were boiled to inacti-
vate the glycosidases, then ﬂuorotagged with 2-aminoacridone, electro-
phoresed on high percentage polyacrylamide gels and analysed for the
presence of speciﬁc keratanase II or EbG products, as described [17].
2.5. Bioactivity of perlecans with FGF-1 and FGF-7
The ability of puriﬁed perlecans to stimulate a heparin-dependent
biological response to FGF-1 and FGF-7 was examined in the
HSPG-deﬁcient myeloid cell line, BaF32 expressing FGFR2b [18].
FGFR2IIIb cells were resuspended in RPMI 1640 medium containing
10% FCS, at 6 · 105 cells/50 ll/well. The wells contained ﬁnal concen-
trations of either 2 lg/mL heparin or 1.25 lg/mL perlecan, together
with 5 nM FGF-1 or FGF-7. To measure cell proliferation, cells were
incubated for 40 h, then labelled with [3H]-thymidine for 6 h. The cells
were washed three times with PBS, prior to scintillation counting. The
results are representative of at least four separate experiments.3. Results
3.1. Identiﬁcation of perlecan glycosaminoglycans by ELISA
assay
In previous studies we have found that perlecan isolated
from HUAEC, other endothelial cell lines and colon carci-
noma cell lines contains only HS chains [10,11,16]. In this
study we have examined perlecan expressed by HEK-293 cells.
Western blotting showed that HEK-293 perlecan, like
HUAEC perlecan, was susceptible to fragmentation and was
immunoreactive with antibodies A76 and 10E4. The HEK-
293 perlecan and its fragments were also reactive with the
CS56 antibody that recognises CS and, surprisingly, the 5D4
antibody that recognises KS (Fig. 1A). The 5D4-reactive
bands co-migrated with native, intact perlecan, as well as the
slowest migrating fragment (Fig. 1A, lane 6). The absence of
any other 5D4 bands on the gel conﬁrms that the perlecan
preparation was free of contaminating KS proteoglycans.
When examined by ELISA (Fig. 1B), the immunoreactivity
of the HEK-293 perlecan with antibody 10E4, relative to anti-
body A76, was noticeably less than we have observed previ-ously for HUAEC perlecan. Furthermore, the 10E4 reactive
HS was refractile to heparanase digestion. Together these
observations suggest that HS on HEK-293 perlecan has a
microstructure that is distinct from HUAEC perlecan; HS
on HEK-293 perlecan may have more extensive regions of
N-sulphation, making it less reactive with 10E4 and less
susceptible to digestion with heparatinase.
We were surprised that this preliminary examination showed
KS on HEK-293 perlecan. To further examine this ﬁnding, we
digested perlecan, coated onto wells of ELISA plates, with hep-
aritinase, chondroitinase ABC or keratanase, to depolymerise
HS, CS and KS, respectively, and eliminate their immunoreac-
tivity. The results showed that, in addition to HS chains,
HEK-293 perlecan was also substituted with CS andKS. Immu-
noreactivity with antibody CS56 was reduced by approximately
50% following digestion with chondroitinase ABC, and immu-
noreactivitywith antibody 5D4was decreased by approximately
85% following digestion with keratanase II. Digestion with
N-glycosidase F did not reduce immunoreactivity with 5D4 sug-
gesting that KS is not N-linked to the core protein (data not
shown). Although hybrid perlecans containing HS and CS have
been described previously, this is the ﬁrst report of perlecan
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with three diﬀerent glycosaminoglycan chains.
3.2. Analysis of perlecan KS
To further examine perlecan glycosaminoglycans, HUAEC
and HEK-293 cells were biosynthetically labelled with [3H]-
glucosamine. Perlecan from each cell type was digested with
keratanases and fractionated on a Biogel P-10 column
(Fig. 2). The results showed that all the [3H]-labelled glycos-
aminoglycans associated with the HUAEC perlecan eluted at
the void volume of the column, indicating that this perlecan
was not sensitive to digestion by keratanases (Fig. 2B). In con-
trast, 15% of the [3H]-labelled glycosaminoglycans associated
with HEK-293 perlecan was recovered at the total volume of
the column, indicating that a proportion of glycosaminoglycan
chains on HEK-293 perlecan are sensitive to keratanase treat-
ment and were digested to di-, tri- or tetrasaccharides
(Fig. 2A).
To further conﬁrm that HEK-293 perlecan was substituted
with KS, we analysed it by FACE. The KS hydrolases, kera-
tanase II and EbG, diﬀer in their substrate speciﬁcities, with
keratanase II preferring more highly sulphated sequences,
and EbG preferring less sulphated sequences in the KS
polymer. EbG digestion of KS yields the unsulphated disac-
charide GlcNAc-Gal and the monosulphated disaccharide
GlcNAc6S-Gal. EbG digests of HEK-293 perlecan generated
the monosulphated GlcNAc6S-Gal and small amounts of theA
B
Fig. 2. Detection of KS on perlecan from HEK-293 cells. [3H]-
glucosamine-labelled perlecan puriﬁed from: (A) HEK-293 cells or
(B) HUAEC was digested with keratanases and chromatographed on a
Biogel P-10 column to detect [3H]-labelled keratanase digestion
products at the column Vt.unsulphated GlcNAc-Gal disaccharides (Fig. 3A). The tetra-
saccharide SA-Gal-GlcNAc6S-Gal derived from the chain ter-
minus was also present on HEK-293 perlecan, indicating that
at least some KS chains are capped with sialic acid (Fig. 3A).
Glucose detected in the samples is most likely derived from the
cell culture medium (Fig. 4).
Keratanase II digestion of KS yields the monosulphated
disaccharide Gal-GlcNAc6S, and the disulphated disaccharide
Gal6S-GlcNAc6S. Keratanase II digests of HEK-293 perlecan
generated the speciﬁc disulphated product, Gal6S-GlcNAc6S
(Fig. 3B). The expected monosulphated disaccharide, Gal-
GlcNAc6S was not detected; instead we detected free galactose
and free GlcNAc, due to the presence of contaminating exo-
glycosidase activity found in some preparations of keratanase
II, as described by Plaas et al. [17]. The presence of the disulph-
ated Gal6s-GlcNAc6s in keratanase II digests, together with
the presence of the unsulphated GlcNAc-Gal, the monosulph-
ated GlcNAc6S-Gal and the monosulphated tetrasaccharide
SA-Gal-GlcNAc6S-Gal in EbG digests, conﬁrms that HEK-
293 perlecan is substituted with KS.
3.3. Bioactivity of FGF-1 and -7 in the presence of perlecans
We and others have shown that HS is essential for FGF-2
signalling through FGF receptors. Furthermore, we have
shown that diﬀerences in HS microstructure signiﬁcantly
inﬂuence this signalling [19]. It was therefore important toFig. 3. Identiﬁcation of KS disaccharides by FACE. Perlecan puriﬁed
from HEK-293 cells was digested with keratanase II or EbG and
analysed by FACE. Non-speciﬁc bands are marked with asterisks.
Fig. 4. Analysis of the growth-promoting activity of perlecan from HUAEC or HEK-293 cells. FGFR2IIIb-expressing BAF32 cells were incubated in
the presence of 2 lg/mL heparin, or 1.25 lg/mL HUAEC-perlecan, or HEK-293 perlecan, together with 5 nM FGF-1 (shaded boxes) or FGF-7
(unﬁlled boxes). Cell growth was measured by incorporation of [3H]-thymidine. The error bars shown indicate the standard deviation of three
replicate values from one representative experiment.
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droitin and HS chains, was able to promote cell growth in an
in vitro assay. BAF32 cells expressing the FGFR2 domain IIIb
splice variant were incubated with FGF-1 or FGF-7, and cell
proliferation measured in the presence of either heparin,
HUAEC perlecan or HEK-293 perlecan. Heparin strongly
stimulated BAF32 cell growth in the presence of both FGF-1
and FGF-7, as reported [18]. HUAEC perlecan stimulated cell
growth to approximately 78% of the level seen with heparin, in
the presence of both FGF-1 and FGF-7. HEK-293 perlecan on
the other hand failed to stimulate cell growth, indicating that
the complement of glycosaminoglycans on HEK-293 perlecan
is unable to bind FGF-1 or FGF-7 and/or facilitate dimerisa-
tion of the FGF2R.4. Discussion
This is the ﬁrst report of a KS-containing perlecan. Most KS
proteoglycans, such as keratocan, mimecan, and lumican carry
KS chains only. A very small number of proteoglycans, includ-
ing aggrecan [20], phosphocan [21] and a variant form of the
hyaluronan receptor CD44, epican [22], carry KS in combina-
tion with CS. Interestingly, aggrecan [9], CD44 [22], and now
perlecan, are the only proteoglycans that can be substituted
with three distinct glycosaminoglycan types. Using immunore-
activity to 5D4, sensitivity to keratanase, and FACE analysis,
we conﬁrmed the presence of KS on HEK-293 perlecan and
showed that it comprised approximately 15% of total glycos-
aminoglycan content. FACE analysis revealed that a propor-
tion of the KS chains were modiﬁed with sialic acid.
In cornea, the KS proteoglycans lumican and keratocan are
critical for corneal transparency [23,24] and mice with homo-
zygous null mutations in these genes have signiﬁcant corneal
pathology [25]. KS in the brain and CNS is thought to modu-
late neuronal development by regulating mossy ﬁbre out-
growth and regeneration [26,27]. In cartilage, KS in the
interglobular domain is thought to potentiate aggrecan cleav-
age by metalloenzymes [28,29]. At present there are no clues
as to what role perlecan KS may play in normal tissue homeo-
stasis or pathology.In contrast to its HS-substituted homologue, HEK-293 perl-
ecan was unable to promote FGF signaling. This is similar to
the HS-modiﬁed perlecan from the WiDR colon carcinoma
cell line that also failed to promote FGF signaling [19]; it high-
lights the fact that FGF signaling through HS is highly depen-
dent upon the microstructure of the HS polymer. Although the
HEK-293 HS chains were moderately immunoreactive with
10E4, they were resistant to heparitinase cleavage. Because
10E4 requires both N-sulfated and N-acetylated disaccharide
units [30], and heparitinase has less reactivity towards highly
sulfated domains, the HEK-293 perlecan may contain a rela-
tively higher proportion of N-sulfated regions. It will be impor-
tant to determine in future studies, what properties are
conferred on HEK-293 perlecan by its heparatinase-resistant
HS and complement of CS and KS chains.
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